etomoxir has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, G; Li, J; Liu, J; Miao, P; Song, S; Sun, X; Zhang, T; Zhao, L; Zhao, S; Zhao, X; Zhou, X | 1 |
| Al-Khami, AA; Hernandez, C; Hossain, F; Maj, T; Ochoa, AC; Reiss, K; Rodriguez, PC; Trillo-Tinoco, J; Valle, LD; Wyczechowska, D; Zheng, L; Zou, W | 1 |
2 other study(ies) available for etomoxir and Lung Neoplasms
| Article | Year |
|---|---|
Inhibition of lipolysis by mercaptoacetate and etomoxir specifically sensitize drug-resistant lung adenocarcinoma cell to paclitaxel.
Topics: Adenocarcinoma; Antineoplastic Agents; Carbon Dioxide; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epoxy Compounds; Glucose; Glycolysis; Humans; Lipolysis; Lung Neoplasms; Oleic Acid; Oxidative Phosphorylation; Paclitaxel; Thioglycolates | 2013 |
Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies.
Topics: Animals; Antineoplastic Agents; Antioxidants; Colonic Neoplasms; Combined Modality Therapy; Drug Evaluation, Preclinical; Energy Metabolism; Epoxy Compounds; Fatty Acids; Female; Humans; Immune Tolerance; Immunotherapy, Adoptive; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice, Inbred C57BL; Myeloid Cells; Oxidation-Reduction; Tumor Microenvironment | 2015 |